Faculty Research

  • Development of an actionable framework to address cancer care disparities in medically underserved populations in the US:expert roundtable recommendations. Winkfield KM, Regnante JM, Miller-Sonet E, Gonzalez ET, Freund KM, Doykos PM. JCO Oncol Pract. 2021;17:e278-e293. PMID: 33464925

    Intravesical anti-PD-1 immune checkpoint inhibition treats urothelial bladder cancer in a mouse model. Kirschner AN, Wang J, Rajkumar-Calkkins A, Neuzil KE, Chang SS. J Urol. 2021;205:1336-1343. PMID: 33356477

    Treatment de-intensification for HPV-positive oropharynx cancer: what is currently acceptable? Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. J Clin Oncol. 2021;39:2732-2733. PMID: 34043410

    Impact of COVID-19 on presentation, staging, and treatment of head and neck mucosal squamous cell carcinoma. Stevens MN, Patro A, Rahman B, Gao Y, Liu D, Cmelak AJ, Wiggleton J, Kim YJ, Langerman A, Mannion K, Sinard RJ, Netterville JL, Rohde SL, Topf MC. Am J Otolaryngol. 2021;43:103263. PMID: 34653954

    Noninvasive thalamotomy for refractory tremor by frameless radiosurgery. Khattab MH, Cmelak AJ, Sherry AD, Luo G, Wang L, Yu H, Hedera P, Phibbs FT, Lindsell CJ, Neimat J, Kirschner AN. Int J Radiat Oncol Biol Phys. 2021;S0360-3016. PMID: 34454047

    Intergroup randomized phase III study of post-operative oxaliplatin, 5-FU, and leucovorin versus oxaliplatin, 5-FU, leucovorin, and bevacizumab for patients with stage II or III rectal cancer receiving preoperative chemoradiation: a trial of the ECOG-ACRIN research group (E5204). Chakravarthy AB, Zhao G, Meropol NK, Flynn PK, Wagner LI, Sloan J, Diasio RB, Mitchell EP, et al. Oncologist. 2020;25:e798-e807. PMID 31852811

    Lessons from COVID19: addressing health equity in cancer care. Siker ML, Deville C, Suneja G, Winkfield K. Int J Radiat Oncol Biol Phys. 2020;108:475-478. PMID: 32890537

    Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity. Sherry AD, Mayer IA, Ayala-Peacock DN, Abramason VG, Rexer BN, Chakravarthy AB. Clin Breast Cancer. 2020;20:344-352. PMID: 32234364

    Circulating tumor DNA as a biomarker of radiographic tumor burden in SCLC. Smith JT, Balar A, Lakhani DA, Kluwe C, Zhao Z, Kopparapu P, Almodovar PK, Muterspaugh A, Yan Y, York S, Horn L, Antic S, Bertucci C, Shaffer T, Hodsdon L, Garg K, Hosseini SA, Lim L, Osmundson E, Massion PP, Lovly CM, Iams W. JTO Clin Res Rep. 2020;2:100110. PMID: 34589992

    ECOG-ACRIN 2399: analysis of patient related outcomes after chemoradiation for locally advanced head and neck cancer. Cmelak AJ, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA. Cancers Head Neck. 2020;5:12. PMID: 33353553

    Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castrate resistant prostate cancer. Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN. J Immunother Cancer. 2019;7:218. PMID: 31412954

    Radiotherapy for ablation of ventricular tachycardia: assessing collateral dosing. John RM, Shinohara ET, Price MP, Stevenson WG. Comput Biol Med. 2018 Nov;102:376-380. PMID: 30126615

    Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design. Rana N, Chakravarthy AB, Kachnic L. Curr Treat Options Oncol. 2017 Feb;18(2):13.

    E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. J Clin Oncol. 2016 Dec 28.

    Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.​ J Clin Oncol. 2017 Apr 1;35(10):1070-1077

    Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC, Chang DT. Radiother Oncol. 2017 Jan;122(1):130-136. 

    Central Nervous System Disease, Education, and Race Impact Radiation Refusal in Pediatric Cancer Patients. Patel CG, Stavas M, Perkins S, Shinohara ET.  J Pediatr Hematol Oncol. 2017 Jul;39(5):382-387

    Margin of error for a frameless image guided radiosurgery system: Direct confirmation based on posttreatment MRI scans. Luo G, Neimat JS, Cmelak A, Kirschner AN, Attia A, Morales-Paliza MDing GX. Pract Radiat Oncol. 2017 May - Jun;7(3):e223-e231

    Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy. Smith CA, Mont S, Traver G, Sekhar KR, Crooks PA, Freeman ML. Oncotarget. 2016 Nov 22;7(47):77926-77936. 

    Accumulation of isolevuglandin-modified protein in normal and fibrotic lung. Mont S, Davies SS, Roberts Second LJ, Mernaugh RL, McDonald WH, Segal BH, Zackert W, Kropski JA, Blackwell TS, Sekhar KR, Galligan JJ, Massion PP, Marnett LJ, Travis EL, Freeman ML. Sci Rep. 2016 Apr 27;6:24919.

    Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15.

    Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A. Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.

    ​Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. Santivasi WL, Wang H, Wang T, Yang Q, Mo X, Brogi E, Haffty BG, Chakravarthy AB, Xia F. Br J Cancer. 2015 Jul 28;113(3):453-9. doi: 10.1038/bjc.2015.208. Epub 2015 Jun 9.  

Clinical Faculty

Natalie Lockney, MD

Leo Luo, MD

focuses on identifying therapy predictive and prognostic markers to improve risk stratification algorithms, adapt current cancer therapies, and monitor treatment response and toxicities in patients with lung and other cancers.   He is the Principal Investigator on several investigator-initiated clinical trials designed to enhance the synergy between radiation therapy and immunotherapy, and is the Vanderbilt site lead on several national clinical trials.  He is an active participant in national organizations that help define the standard of care for cancer patients and guide new areas of research direction.  

Ashwin Shinde, MD

interest is in comparative effectiveness research and improvement of patient outcomes, especially in controversial clinical scenarios without effective guidelines to management. He has co-authored over 30 manuscripts/editorials and has been the first author on over 20 of those.

interests include improving outcomes and reducing side effects using devices and refinements to current radiation techniques as well as examining new indications for radiation

Ryan Whitaker, MD, PhD

Karen Winkfield, MD, PhD

 a national expert in community engagement with research focused on the design and implementation of programming to reduce sociocultural and economic barriers that contribute to disparate health outcomes for racial/ethnic minorities and underserved populations. In September 2021, Dr. Winkfield was appointed by U.S. president Joe Biden to a six-year term on the National Cancer Advisory Board. She serves as Executive Director of the Meharry-Vanderbilt Alliance.

Research Faculty

His research interests include: accurate patient treatment planning, accurate dose calibration for radiation beams, quality assurance (QA) in reference dosimetry and patient treatment planning systems, Image Guided Radiation Therapy (IGRT), adaptive radiotherapy, stereotactic body radiation therapy (SBRT), reducing imaging guidance dose to patients, application of highly accurate Monte Carlo techniques in patient dose calculations, small-field dosimetry, developing new treatment delivery techniques using electrons and photon beams, developing accurate and practical dose calculation algorithms for low energy photon beams.